📣 VC round data is live. Check it out!
- Public Comps
- Carmat
Carmat Valuation Multiples
Discover revenue and EBITDA valuation multiples for Carmat and similar public comparables like SpectraCure, AMA Corp, Pheton Holdings, enVVeno Medical and more.
Carmat Overview
About Carmat
Carmat is a France-based company dedicated to designing, manufacturing, and marketing Aeson, the artificial heart. The company's mission is to establish Aeson as the primary alternative to heart transplantation, offering a life-saving therapeutic option for patients with end-stage biventricular heart failure who face a severe shortage of donor hearts.
Founded
2008
HQ

Employees
153
Website
Financials (FY)
EV
$72M
Valuation Multiples
Start free trialCarmat Stock Performance
Carmat has current market cap of $7M, and enterprise value of $72M.
Market Cap Evolution
Carmat's stock price is $0.11.
Carmat share price decreased by 70.0% in the last year.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $72M | $7M | 0.0% | - | - | -70.0% | - |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCarmat Valuation Multiples
Carmat Financial Valuation Multiples
As of June 3, 2026, Carmat has market cap of $7M and EV of $72M.
| LTM | Last FY | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Carmat Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Carmat Competitors
Carmat competitors include SpectraCure, AMA Corp, Pheton Holdings, enVVeno Medical, Bio-Gate, Redsense Medical, Zynex, PharmaCyte Biotech, Qlife Holding and Modne Zakupy.
Most Carmat public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | - | (2.3x) | - | |||
| 3.6x | - | (1.4x) | - | |||
| - | - | - | - | |||
| - | - | 0.8x | - | |||
| 0.8x | 0.8x | (6.7x) | (11.5x) | |||
| 2.3x | - | (8.3x) | - | |||
| - | - | - | - | |||
| - | - | 2.6x | - | |||
This data is available for Pro users. Sign up to see all Carmat competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Carmat
| When was Carmat founded? | Carmat was founded in 2008. |
| Where is Carmat headquartered? | Carmat is headquartered in France. |
| How many employees does Carmat have? | As of today, Carmat has over 153 employees. |
| Is Carmat publicly listed? | Yes, Carmat is a public company listed on Berlin Stock Exchange. |
| What is the stock symbol of Carmat? | Carmat trades under CXT ticker. |
| When did Carmat go public? | Carmat went public in 2010. |
| Who are competitors of Carmat? | Carmat main competitors include SpectraCure, AMA Corp, Pheton Holdings, enVVeno Medical, Bio-Gate, Redsense Medical, Zynex, PharmaCyte Biotech, Qlife Holding, Modne Zakupy. |
| What is the current market cap of Carmat? | Carmat's current market cap is $7M. |
| Is Carmat profitable? | No, Carmat is not profitable. |
| How many companies Carmat has acquired to date? | Carmat hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Carmat has invested to date? | Carmat hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Carmat
Lists including Carmat
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.